Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Week in Review

Summaries of each week's events in China biotech are provided free to all readers.  A weekly email newsletter providing direct links to these articles is also available - click here for free email newsletter...

Week in Review: Tang Capital Offers $465 Million for LianBio Plus 80% of any Licenses/Divestments

Week in Review: BeiGene Signs $1.3 Billion Deal for Preclinical CDK2 Inhibitor from Boston’s Ensem

Week in Review: Legend Partners DLL3 CAR-T Candidate with Novartis in $1.2 Billion Deal

Week in Review: Eccogen Out-licenses GLP-1 Agonist to AstraZeneca in $2 Billion Deal

Week in Review: Hengrui Out-Licenses Next-Gen PARP1 to Merck KGaA for $1.7 Billion

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital